Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

Other analysts have also issued research reports about the stock. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Oppenheimer boosted their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Truist Financial increased their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Stephens started coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $38.64.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $26.97 on Monday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $30.58. The business has a 50 day moving average price of $24.29 and a two-hundred day moving average price of $23.49. The firm has a market cap of $3.94 billion, a PE ratio of -14.74 and a beta of 1.56.

Insiders Place Their Bets

In related news, insider Mario Alberto Accardi sold 10,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This trade represents a 5.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,961 shares of company stock worth $1,304,878 over the last quarter. 7.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its holdings in shares of Centessa Pharmaceuticals by 34.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock valued at $364,034,000 after buying an additional 3,747,475 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 12.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock worth $282,156,000 after acquiring an additional 1,246,741 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 24.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock worth $134,480,000 after acquiring an additional 1,045,750 shares during the last quarter. Siren L.L.C. raised its position in shares of Centessa Pharmaceuticals by 24.8% during the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after purchasing an additional 800,000 shares during the period. Finally, Commodore Capital LP lifted its holdings in shares of Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after purchasing an additional 930,711 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.